FR2894145B1 - Utilisation de facteur h du complement a titre de medicament - Google Patents

Utilisation de facteur h du complement a titre de medicament

Info

Publication number
FR2894145B1
FR2894145B1 FR0512404A FR0512404A FR2894145B1 FR 2894145 B1 FR2894145 B1 FR 2894145B1 FR 0512404 A FR0512404 A FR 0512404A FR 0512404 A FR0512404 A FR 0512404A FR 2894145 B1 FR2894145 B1 FR 2894145B1
Authority
FR
France
Prior art keywords
complement
factor
medicinal product
medicinal
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0512404A
Other languages
English (en)
Other versions
FR2894145A1 (fr
Inventor
Bernadette Cauvin
Frederic Dhainaut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0512404A priority Critical patent/FR2894145B1/fr
Application filed by LFB SA filed Critical LFB SA
Priority to CN2012101497188A priority patent/CN102988958A/zh
Priority to BRPI0619728-0A priority patent/BRPI0619728A2/pt
Priority to CNA2006800521939A priority patent/CN101336111A/zh
Priority to EP06841898A priority patent/EP1962885A2/fr
Priority to US12/095,949 priority patent/US20080318841A1/en
Priority to AU2006323849A priority patent/AU2006323849B2/en
Priority to PCT/FR2006/002693 priority patent/WO2007066017A2/fr
Priority to JP2008543870A priority patent/JP2009518368A/ja
Priority to CA002633102A priority patent/CA2633102A1/fr
Priority to KR1020087016073A priority patent/KR20080091441A/ko
Publication of FR2894145A1 publication Critical patent/FR2894145A1/fr
Priority to IL191931A priority patent/IL191931A0/en
Application granted granted Critical
Publication of FR2894145B1 publication Critical patent/FR2894145B1/fr
Priority to JP2012168827A priority patent/JP2012211189A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FR0512404A 2005-12-07 2005-12-07 Utilisation de facteur h du complement a titre de medicament Expired - Fee Related FR2894145B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR0512404A FR2894145B1 (fr) 2005-12-07 2005-12-07 Utilisation de facteur h du complement a titre de medicament
KR1020087016073A KR20080091441A (ko) 2005-12-07 2006-12-07 인자 ｈ 농축물의 제조방법 및 약물의 형태로서의 그의용도
CNA2006800521939A CN101336111A (zh) 2005-12-07 2006-12-07 制备h因子浓缩物的方法及其药物用途
EP06841898A EP1962885A2 (fr) 2005-12-07 2006-12-07 Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament
US12/095,949 US20080318841A1 (en) 2005-12-07 2006-12-07 Method For Preparing a Factor H Concentrate and the Use Thereof in the Form of a Drug
AU2006323849A AU2006323849B2 (en) 2005-12-07 2006-12-07 Method for preparing a factor H concentrate and the use thereof in the form of a drug
CN2012101497188A CN102988958A (zh) 2005-12-07 2006-12-07 制备h因子浓缩物的方法及其药物形式的用途
JP2008543870A JP2009518368A (ja) 2005-12-07 2006-12-07 因子ｈ濃縮物の調製方法及び薬剤の形でのその使用
CA002633102A CA2633102A1 (fr) 2005-12-07 2006-12-07 Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament
BRPI0619728-0A BRPI0619728A2 (pt) 2005-12-07 2006-12-07 método de preparação de um concentrado de fator h e utilização deste concentrado de fator h a tìtulo de medicamento
PCT/FR2006/002693 WO2007066017A2 (fr) 2005-12-07 2006-12-07 Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament
IL191931A IL191931A0 (en) 2005-12-07 2008-06-03 Method for preparing a factor h concentrate and the use thereof in the form of a drug
JP2012168827A JP2012211189A (ja) 2005-12-07 2012-07-30 因子ｈ濃縮物の薬剤の形での使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0512404A FR2894145B1 (fr) 2005-12-07 2005-12-07 Utilisation de facteur h du complement a titre de medicament

Publications (2)

Publication Number Publication Date
FR2894145A1 FR2894145A1 (fr) 2007-06-08
FR2894145B1 true FR2894145B1 (fr) 2008-10-17

Family

ID=36928796

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0512404A Expired - Fee Related FR2894145B1 (fr) 2005-12-07 2005-12-07 Utilisation de facteur h du complement a titre de medicament

Country Status (11)

Country Link
US (1) US20080318841A1 (fr)
EP (1) EP1962885A2 (fr)
JP (2) JP2009518368A (fr)
KR (1) KR20080091441A (fr)
CN (2) CN102988958A (fr)
AU (1) AU2006323849B2 (fr)
BR (1) BRPI0619728A2 (fr)
CA (1) CA2633102A1 (fr)
FR (1) FR2894145B1 (fr)
IL (1) IL191931A0 (fr)
WO (1) WO2007066017A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038995A1 (fr) 2005-09-19 2007-04-12 Csl Behring Gmbh Facteur h pour le traitement de néphropathies chroniques et sa production
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
SI2894165T1 (sl) 2008-11-10 2023-04-28 Alexion Pharmaceuticals, Inc. Postopki in sestavki za zdravljenje motenj povezanih s komplementom
GB0904427D0 (en) 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
AT516600B1 (de) * 2009-07-23 2016-07-15 Baxter Int Herstellung von faktor h (fh) und fh-derivaten aus plasma
FR2952539B1 (fr) 2009-11-16 2012-01-13 Lab Francais Du Fractionnement Preparation d'un concentre de facteur h
FR2952640B1 (fr) 2009-11-16 2012-12-07 Lab Francais Du Fractionnement Procede de fabrication d'une preparation de facteur h
EP2533797A1 (fr) 2010-02-12 2012-12-19 CeMM Forschungszentrum für Molekulare Medizin GmbH Facteur h du complément pour états pathologiques de stress oxydatif
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
CN103153333B (zh) * 2010-10-13 2015-09-09 欧克塔医药公司 补体因子h的纯化方法
FR2967071A1 (fr) 2010-11-10 2012-05-11 Lab Francais Du Fractionnement Facteur h pour le traitement de maladies auto-immunes du systeme nerveux
FR2981661B1 (fr) * 2011-10-25 2015-06-19 Lfb Biotechnologies Procede de preparation du facteur h humain
FR2983212A1 (fr) 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
LT2968457T (lt) 2013-03-14 2018-10-25 Baxalta Incorporated Transplantacijos veiksnys h
AU2014236782B2 (en) 2013-03-14 2019-01-03 Baxalta GmbH Factor H for treatment of rheumatoid arthritis
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
AU2013203048A1 (en) 2013-03-15 2014-10-02 Baxalta GmbH Isolation of factor h from fraction i paste
JP6211701B2 (ja) 2013-08-07 2017-10-11 アレクシオン ファーマシューティカルズ， インコーポレイテッド 非典型溶血性***症候群のバイオマーカータンパク質
MX2017002277A (es) * 2014-08-20 2017-08-10 Stichting Sanquin Bloedvoorziening Anticuerpos que potencian el factor h y sus usos.
BR112022000739A2 (pt) 2019-07-17 2022-04-12 Gemini Therapeutics Sub Inc Anticorpos de potencialização de fator h e usos dos mesmos
CN113045634B (zh) * 2019-12-28 2023-04-28 四川远大蜀阳药业有限责任公司 一种补体h因子制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
GB9624731D0 (en) * 1996-11-28 1997-01-15 Univ Leicester Complement inhibitor
US20030190732A1 (en) * 2000-10-13 2003-10-09 Djuro Josic Plasma fraction containing bikunin, method for the production thereof and use of the same
EP1336618A1 (fr) * 2002-02-15 2003-08-20 HANS-KNÖLL-INSTITUT FÜR NATURSTOFF-FORSCHUNG e.V. Facteur H du complement de porc et son utilisation
WO2007038995A1 (fr) * 2005-09-19 2007-04-12 Csl Behring Gmbh Facteur h pour le traitement de néphropathies chroniques et sa production

Also Published As

Publication number Publication date
IL191931A0 (en) 2009-02-11
CA2633102A1 (fr) 2007-06-14
BRPI0619728A2 (pt) 2011-10-11
EP1962885A2 (fr) 2008-09-03
US20080318841A1 (en) 2008-12-25
FR2894145A1 (fr) 2007-06-08
WO2007066017A3 (fr) 2007-11-08
JP2009518368A (ja) 2009-05-07
CN102988958A (zh) 2013-03-27
JP2012211189A (ja) 2012-11-01
WO2007066017A2 (fr) 2007-06-14
AU2006323849A1 (en) 2007-06-14
KR20080091441A (ko) 2008-10-13
CN101336111A (zh) 2008-12-31
AU2006323849B2 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
FR2894145B1 (fr) Utilisation de facteur h du complement a titre de medicament
DE602004017510D1 (de) Medizinprodukt vom kapseltyp
DK1907037T4 (da) Lægemiddeldispenser
DK2151438T3 (da) Lægemiddel indeholdende PPAR-Deltaagonist
IL183101A (en) Use of tetrahydrocannabivarin in drug production
SI1957073T1 (sl) Medicinsko zdravilo
DE602005002413D1 (de) Wegwerfhöschen
FR2867064B1 (fr) Doseur de medicaments
DE602006013636D1 (de) Dosiszähler
HK1119070A1 (en) Use of trans-clomiphene in the manufacture of medicines
IL183929A0 (en) Use of inerferon - ?? in the preparation of a medicament
IS7564A (is) Lyfjablanda með breytta losun
FIU20070081U0 (fi) Saniteettituote
EP1757282A4 (fr) Utilisation de composes de kaurane dans l'elaboration d'un medicament
FR2904318B1 (fr) Derives de pyrimidinone et leur utilisation comme medicament
FR2920776B1 (fr) Utilisation de derives de purine pour la fabrication d'un medicament
ZA201005396B (en) 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative,use thereof,and medicament containing the derivative
IL188241A0 (en) Cripowellins and synthetic derivatives thereof used as medicaments
TWM292546U (en) Medicament counter
FR2907784B1 (fr) Derives phenyliques et leur utilisation comme medicament
UA10110S (uk) Розгортка упаковки лікарського засобу
UA10109S (uk) Розгортка упаковки лікарського засобу
UA10535S (uk) Упаковка фармацевтичного засобу
UA10843S (uk) Упаковка фармацевтичного засобу
UA10054S (uk) Упаковка фармацевтичного засобу

Legal Events

Date Code Title Description
CJ Change in legal form
RM Correction of a material error
ST Notification of lapse

Effective date: 20150831